PeptideStack
5.2kquestions
20kanswers
220users

How do I reconcile 98.8% from Medutest with 98.4% from the supplier?

Asked 16 Sept 2024Modified 19 months agoViewed 25k times
34

Stated plainly: 98.8% · Medutest · 98.4%.

I noticed this today and I have not touched anything since, in case the state is diagnostic.

I have not discarded anything yet, so a test is still possible if that is the recommendation.

How do I distinguish the benign explanation from the one that matters?

purity
purity

Purity as chromatographic area per cent - the fraction of detected material that is your target peak. It says nothing about how much material is…

833 questions
batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

910 questions
coa
coa

Certificates of analysis: what fields a useful one carries, how to tell a real analytical report from a marketing document, batch and lot…

771 questions
medutest
medutest

Medutest, one of four independent testing and verification services referenced throughout this site. Use this tag for its methods, its report…

126 questions
shareeditfollowflag
TI
askedteodora_ilic17k2716 Sept 2024

5 Answers

Sorted by votes
70

0.4 percentage points, and the direction is the informative half. Medutest reports 98.8 per cent and the certificate 98.4, so the independent figure is higher. As impurity that is 1.2 per cent against 1.6 — 0.75 times as much unassigned area, which is the unusual direction and worth a second look at the integration. Method differences usually make the independent number the lower one, so an independent result above the certificate points at integration limits, a different wavelength, or a different definition of the main peak rather than at a better vial. Ask both parties for the method section before you decide which figure is wrong, because the answer is often neither.

In practice, the single most important distinction is between what purity measures — the fraction of detected material that is your target — and what you actually want to know — how much of the material in the vial is your target.

Retention time is sequence-specific and method-specific, so comparing your result to a supplier value using a different method is meaningless without method documentation.

Column pore size affects mass transfer — a 100 Angstrom packing on a 5 kDa peptide restricts diffusion, broadening the peak and potentially hiding small impurities in the shoulders.

Compare purity within a single laboratory on the same method, never across laboratories.

shareimprove this answerflag
RT
answeredrune_thoresen16k2813 Dec 2024
3Any reason to prefer ion chromatography over fluorine NMR for the counter-ion here? – Dr_Idris_Coulibaly 5 months ago
4The distinction between purity and content cannot be repeated often enough here. – Dr_Priya_Raghunathan 6 months ago
add a comment
Sponsored

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards
45

Read the chromatogram before you read the number, because the number without the trace is not a measurement, it is a claim.

Buffer versus acid in the mobile phase changes the ionisation state of basic and acidic residues, shifting retention and selectivity — same vial, potentially different separation.

In practice, mobile phase additive choice affects ionisation and peak shape — TFA gives sharp peaks but suppresses mass spectrometry signal, formic acid gives worse peaks but preserves signal.

The ICH Q3A impurity thresholds and the relevant pharmacopoeial chapters all specify method validation requirements that almost no research-grade certificate claims to meet.

If you are ranking vendors, specify a method and have all samples tested at the same place.

shareimprove this answerflag
M4
answeredmz_4113101k35824 Dec 2024
37

The short answer is that two competent laboratories on identical material will disagree, and the disagreement is almost always explainable by method differences.

The fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.

Tailing factor measures peak shape, and a badly tailing peak spreads into the region where small impurities live, forcing tangent-skim integration that assigns tail area to the main peak.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

shareimprove this answerflag
AZ
answeredahmed_zerouali15k174 Jan 2025
29

The honest answer is that the achievable range of plausible purity figures for a given vial is wider than most people expect.

Sample solvent strength affects peak shape — if you inject in strong solvent on a gradient starting in weak solvent, the solvent peak can distort your main peak or create a false shoulder.

One qualification: achieving purity above roughly 98 per cent on a 30-residue peptide is fighting the chemistry of synthesis, not the quality of the purification.

If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.

shareimprove this answerflag
AB
answeredassay_blank45k3818 Sept 2024
3Adding a vote because this deserves more of them. – v_ramaswamy 5 months ago
add a comment
26

Start from what the detector sees, because that tells you what the number means.

Detection wavelength matters because 214 nm sees the peptide backbone while 280 nm sees only aromatic side chains — so truncation impurities lacking a tryptophan are invisible at 280 nm.

The caveat is that purity without identity is only half an answer — a high purity does not mean the peak is actually what you think it is.

In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.

edited 3 Nov 2024 by tobias_reint — added the citation requested in comments

shareimprove this answerflag
TR
answeredtobias_reint20k3830 Oct 2024

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.